Vectura Group PLC (VEC.L)

About

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.41
Market Cap(Mil.):	£705.16
Shares Outstanding(Mil.):	679.34
Dividend:	--
Yield (%):	--

Financials

	VEC.L	Industry	Sector
P/E (TTM):	--	30.90	33.64
EPS (TTM):	--	--	--
ROI:	--	14.75	14.27
ROE:	--	16.25	15.99

Latest News about VEC.L

UPDATE 1-Vectura reviewing drug stockpiles as no-deal Brexit looms

Sept 11 British drugmaker Vectura Group Plc is reviewing its stockpiles of drugs and key components as part of its mitigation plan for a "no-deal" Brexit and warned on Tuesday of a potential disruption to supply chains and higher costs.

11 Sep 2018

Vectura reviewing drug stockpiles as no-deal Brexit looms

Sept 11 Vectura Group Plc is reviewing its stockpiles of drugs and key components as part of its plan for a "no-deal" Brexit, the British drugmaker said on Tuesday, and warned of a potential disruption to supply chains and higher costs.

11 Sep 2018